The USEF Equine Drugs and Medications Rules reminds competitors that cannabinoids (CBD) and their metabolites are prohibited under USEF rules and that, beginning on September 1, 2019, horses competing under USEF rules who test positive for natural cannabinoids, synthetic cannabinoids and other cannabimimetics will be considered in violation of GR4.
In a May 14 press release, USEF officials stated, “While hemp does not contain more than 0.3% THC, it does contain CBD. CBD, both natural and synthetic forms, are likely to effect the performance of a horse due to its reported anxiolytic effects. This substance is no different than legitimate therapeutics that effect mentation and behavior in horses. It is for these reasons that USEF prohibits CBD and all related cannabinoids.”
The USEF has implemented analytical methods of detecting CBD and similar cannabinoids.
The USEF press release also stated, “As published literature does not exist noting detection times of these substances in the horse, and because products can widely vary in their compositions and concentrations, detections prior to September 1 will receive warnings. They will be considered to be in “Prior” violation if there are additional detections of cannabinoids following September 1. GR411 Conditions For Therapeutic Administrations of Prohibited Substances does not apply for cannabinoids and medication report forms do not apply.”
To read the full USEF press release, click here: https://www.usef.org/media/press-releases/usef-announces-positive-tests-of-cannabinoids?utm_source=SilverpopMailing&utm_medium=email&utm_campaign=EQ%20Weekly%20-%2005.14.19%20-%20Non%20Members%20(1)&utm_content=